Related Experiment Video
Updated: Sep 29, 2025

Merging Absolute and Relative Quantitative PCR Data to Quantify STAT3 Splice Variant Transcripts
Published on: October 9, 2016
Nuclear Expression of p-STAT3 Is Associated with Poor Prognosis in ER(-) Breast Cancer
Tsuyoshi Nakagawa1, Goshi Oda1, Hiroshi Kawachi2
1Department of Specialized Surgeries, Graduate School, Tokyo Medical and Dental University, Bunkyou-ku, Tokyo 113-8519, Japan.
Abstract:
The activation of signal transducer and activator of transcription 3 (STAT3) has been reported in several types of cancer, where it acts as an oncogene. However, in breast cancer, the clinical role of STAT3 remains unclear. In the present study, the association between phosphorylated-STAT3 (p-STAT3) expression and clinicopathological/biological factors was examined in each subtype. p-STAT3 expression was examined in 135 cases of breast cancer by immunohistochemistry. p-STAT3 expression was not associated with clinicopathological/biological factors and prognosis in a complete cohort of breast cancer cases. However, in patients with estrogen receptor-negative (ER(-)) breast cancer and triple-negative breast cancer (TNBC), multivariate analysis showed that higher p-STAT3 expression was significantly associated with a short relapse-free survival (p = 0.029, HR 5.37, 95%CI 1.19-24.29). TNBC patients with p-STAT3 overexpression were found to have a poor prognosis (p = 0.029, HR 5.37, 95%CI 1.19-24.29). On the other hand, in ER(+) breast cancer, p-STAT3 overexpression was associated with a favorable prognosis (p = 0.034, HR 9.48, 95%CI 1.18-76.21). The present results suggested that STAT3 expression may play a different role in ER(-) and ER(+) breast cancer. In the future, the pharmacological inhibition of STAT3 expression may serve as an effective therapeutic strategy for ER(-) breast cancer, particularly TNBC.
Related Concept Videos
Abnormal Proliferation
Negative Regulator Molecules
The Nucleolus
The JAK-STAT Signaling Pathway
PI3K/mTOR/AKT Signaling Pathway
mTOR Signaling and Cancer Progression
The mTOR pathway or the...

